Macro Finance
Lilly to Buy Merida for $2.88 Billion in Autoimmune Push
Bloomberg Markets·August 31, 2026·1 min read
Eli Lilly plans to buy Merida Biosciences for up to $2.88 billion in cash to expand in autoimmune and allergic diseases, diversifying beyond weight-loss and diabetes. Lilly has announced over $20 billion in deals in 2026, using Zepbound and Mounjaro profits to target earlier-stage medicines.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.